Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer

BMC Cancer

Table 1 Demographic and pathologic details for 69 NSCLC patients

Variable (number of patients assessed)	Number	Percentage (95% CI)
Gender (69)
Male	42	61 (49-72)
Female	27	39 (28-51)
Age at definitive treatment (years) (69)
Median (range)	70 (29 - 85)
Histology (69)
AC	30	43 (32-55)
SCC	23	33 (23-45)
LCC	16	23 (14-34)
Smoking status (69)
Never	16	23 (14-34)
Current/Ex	53	77 (66-86)
Stage (69)
IA	16	23 (14-34)
IB	26	38 (27-49)
IIA	3	4 (1-11)
IIB	7	10 (5-19)
IIIA	8	12 (6-20)
IIIB	3	4 (1-11)
IV	5*	12 (6-20)
Unknown	1#	1 (0-7)
Primary tumour size (mm) (69)
0 - 20	23	33 (23-45)
21 - 30	10	15 (8-24)
31 - 50	22	32 (22-43)
51 - 70	5	7 (3 - 16)
>70	7	10 (5 - 20)
Unknown	2^	3 (0-9)
T < 40 mm, N1 &/or M1 (69)	13	19 (11-29)
T > 40 mm, N0M0 (69)	11	16 (9-26)
T > 70 mm, N0M0 (69)	4	6 (2-13)
*K-Ras* mutation (46)**	10	21 (11-34)
EGFR mutation (46)**	5	11 (4-22)
*P53* mutation (69)	26 +/- 17
Definite	26	38 (27-49)
Possible	17	25 (16-36)
Recurrence (68)+	28	41 (30-53)
Death from NSCLC (68)+	23	34 (23-45)
Time from surgery to death (months) (23)
Median (range)	19 (7 - 73)

AC = adenocarcinoma; LCC = large cell carcinoma; SCC = squamous cell carcinoma
*3 patients had solitary cerebral metastases resected at diagnosis, 1 patient had 2 separate lung lesions (unclear if synchronous primary lesions or pulmonary metastasis), 1 patient had disseminated disease
# Stage unable to be determined in 1 patient after wedge resection without nodal dissection.
^ Tumour size unable to be assessed in 1 patient who underwent incomplete tumour resection after combined chemoradiation, and one who had incomplete resection of an obstructing stage IIIA tumour followed by definitive radiotherapy.
** Only AC and LCC samples were tested for mutations of K-Ras and EGFR.
+One patient with disseminated disease at diagnosis excluded from recurrence and survival analysis

ISSN: 1471-2407